ea0083erco3 | Endocrine-related Cancer | EYES2022
A Barac Nekic
, K Zibar Tomsic
, L Sambula
, I. D. Vodanovic
, T. Dusek
, D. Kastelan
Introduction: Mitotane is an adrenolytic drug which is used in patients with adrenocortical carcinoma (ACC) and leads to adrenal insufficiency (AI). The aim of this study was to evaluate the time to recovery of the hypothalamus-pituitary-adrenal (HPA) axis after adjuvant mitotane treatment and to determine possible predictive factors.Materials and Methods: In this retrospective study, we included 19 patients with ACC, ENSAT stage I- III, who were treated...